Blue Note logo


Creating a New Way Forward

Working closely with leading cancer centers, community oncology clinics, and teams of patients, Blue Note is developing clinically validated prescription digital therapeutics to help reduce anxiety, depression, and other distress related to cancer.


Robert Carbajal

Senior Mobile Engineer (Interim)

Sarah Chamberlain

Senior Product Designer

Carlos Craig

Mobile Engineer: React Native

Josh Donahey

Senior Design Quality Assurance Engineer

Alexia Downs

Director, Patient and Business Operations

Geoff Eich


Jen Feng

Senior Manager, Product Management

Elliott Harris

Patient Service Center Operations Lead

Patrick Kwon

Project Manager, Product Management

My Luu

Director, Human Resources

Michael Malecki, PhD

Head of Access & Reimbursement

David Rigby

JavaScript Engineer

Jade Rouse

Senior Product Manager & Investor Relations Lead

Michelle Rubin-Onur, PhD

Director of Regulatory and Quality

Dianne Shumay, PhD

Head of Behavioral Science

Kymbrell Smith

Senior Accountant & Financial Analyst

Chloe Taub, PhD

Senior Manager, Clinical Psycho-Oncology

Amber Trivedi

Chief Operating Officer

Kevin Wyllie

Design Quality Assurance Engineer

Sean Zion, PhD

Senior Manager, Behavioral Science Research

Mark Elfers

Business Development Advisor

Lindsay Huffman

Commercialization Advisor

Rick Lit

Regulatory Advisor

Michael McKinley

Product Advisor

Angela Perez

Commercialization Advisor

George Romanko

HR & Talent Advisor

Board of Directors

Gena Cook

Director, Board of Directors

Geoff Eich

Blue Note Therapeutics

Andrew Firlik, MD

Jazz Venture Partners

John Harris

Jazz Venture Partners

Marcus Neubauer, MD

The US Oncology Network

Board of Advisors

Michael Antoni, PhD

Sylvester Comprehensive Cancer Center

Bio  Research

William Breitbart, MD

Memorial Sloan Kettering Cancer Center

Bio  Research

Patricia Ganz, MD

UCLA Jonsson Comprehensive Cancer Center

Bio  Research

Kevin Knopf, MD

UCSF Institute for Health Policy

Bio  Research

Lidia Schapira, MD

Stanford University Medical Center

Bio  Research

Michael Seiden, MD, PhD

Former President, US Oncology Network


Gregory TenBarge, MHA

Chief Administration Officer, Envision Medical Group


Betina Yanez, PhD

Northwestern University Feinberg School of Medicine

Bio  Research

Our Pipeline

Blue Note's products will serve all cancer patients, from early stage through survivorship, in both the in-patient and out-patient settings.

Product Candidate Disease Progression Development Proof of Concept Pivotal Trial FDA Review
BNT001 Diagnosis --> Survivorship
BNT200 Acute Inpatient  
BNT300 Advanced Cancer    
BNT400 Survivorship      
Product Candidate Disease Progression Status
BNT001 Diagnosis --> Survivorship 3
BNT200 Acute Inpatient 2
BNT300 Advanced Cancer 1
BNT400 Survivorship 0
0 = Development
1 = Proof of Concept
2 = Pivotal Trial
3 = FDA Review

We Can't Do This Alone

Blue Note Therapeutics is honored to work with the National Comprehensive Cancer Network (NCCN) and other leading cancer care organizations in our quest to help cancer patients live better.